We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Top Research Reports for Pfizer, Cisco & Southern Company
Read MoreHide Full Article
Friday, November 16, 2018
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE - Free Report) , Cisco (CSCO - Free Report) and Southern Company (SO - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Pfizer’s shares have outperformed its peer group year-to-date (the stock is up +19.2% over this period vs. a +7.2% increase for the Zacks Large-Cap Pharmaceuticals industry). Pfizer beat estimates for earnings while matching the same for in the third quarter.
Pfizer is facing top-line headwinds in the form of genericization of key drugs, supply challenges in the legacy Hospira portfolio, pricing pressure and rising competition. Nevertheless, the Zacks analyst thinks new products like Ibrance, cost-cutting efforts, a lower tax rate and share buybacks can support bottom-line growth.
Pfizer also boasts a strong pipeline and looks well positioned to deliver several potential new breakthrough innovative medicines in the next five years, which can drive long-term growth. Bavencio, though currently approved for two small indications, is being considered a key long-term growth driver for Pfizer if it can gain label expansion approvals. Pfizer also recently gained FDA approval for three new cancer medicines, which can boost oncology sales.
Shares of Cisco have outperformed the Zacks Computer Networking industry over the past year, gaining +30.3% vs. +27.7%. Cisco reported stellar first-quarter results. The Zacks analyst thinks the company is benefitting from expanding footprint in the rapidly growing security market, which represents a significant growth opportunity.
Strong contribution from security, Infrastructure Platforms and applications is a positive. Order strength and improving traction of the subscription-based model are other tailwinds. Strengthening collaboration portfolio which now includes Webex Teams and Accompany bodes well. Partnerships with Telenor, Apple, IBM, Microsoft and Google Cloud are notable.
Further, Duo Security buyout should help the company expand its IT and data security businesses. However, weakness in switching and routing is a headwind. Arista’s intention of manufacturing switches that connect campus networks is likely to hurt Cisco as it holds a dominant position in that market.
Southern Company's shares have outperformed the Zacks Electric Power industry over the past six months, gaining +8.2% vs +6.8%. The Zacks analyst thinks Southern Company is one of the largest and best-managed electric utility holding companies in the United States, dominating the power business across the southeastern region.
With good rate base growth and constructive regulation, it is expected to generate steady earnings and dividend growth in the coming years through long-term power contracts. Additionally, SO's $12 billion AGL Resources buy has significantly increased its customer base and diversified offerings. However, continued timing and cost overrun issues over two large construction projects – Vogtle and Kemper – are major overhangs.
While the $25 billion Vogtle nuclear plant has gone well over budget and is years behind schedule, Southern's Kemper project suffered yet another setback with the suspension of all coal gasification operations amid additional cost burden. Hence, Southern Company warrants a cautious stance from the investors.
Other noteworthy reports we are featuring today include Exelon (EXC - Free Report) , SunTrust Banks (STI - Free Report) and AmerisourceBergen .
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6% and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trendsand Earnings Previewreports. If you want an email notification each time Sheraz publishes a new article, please click here>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top Research Reports for Pfizer, Cisco & Southern Company
Friday, November 16, 2018
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE - Free Report) , Cisco (CSCO - Free Report) and Southern Company (SO - Free Report) . These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Pfizer’s shares have outperformed its peer group year-to-date (the stock is up +19.2% over this period vs. a +7.2% increase for the Zacks Large-Cap Pharmaceuticals industry). Pfizer beat estimates for earnings while matching the same for in the third quarter.
Pfizer is facing top-line headwinds in the form of genericization of key drugs, supply challenges in the legacy Hospira portfolio, pricing pressure and rising competition. Nevertheless, the Zacks analyst thinks new products like Ibrance, cost-cutting efforts, a lower tax rate and share buybacks can support bottom-line growth.
Pfizer also boasts a strong pipeline and looks well positioned to deliver several potential new breakthrough innovative medicines in the next five years, which can drive long-term growth. Bavencio, though currently approved for two small indications, is being considered a key long-term growth driver for Pfizer if it can gain label expansion approvals. Pfizer also recently gained FDA approval for three new cancer medicines, which can boost oncology sales.
(You can read the full research report on Pfizer here >>>).
Shares of Cisco have outperformed the Zacks Computer Networking industry over the past year, gaining +30.3% vs. +27.7%. Cisco reported stellar first-quarter results. The Zacks analyst thinks the company is benefitting from expanding footprint in the rapidly growing security market, which represents a significant growth opportunity.
Strong contribution from security, Infrastructure Platforms and applications is a positive. Order strength and improving traction of the subscription-based model are other tailwinds. Strengthening collaboration portfolio which now includes Webex Teams and Accompany bodes well. Partnerships with Telenor, Apple, IBM, Microsoft and Google Cloud are notable.
Further, Duo Security buyout should help the company expand its IT and data security businesses. However, weakness in switching and routing is a headwind. Arista’s intention of manufacturing switches that connect campus networks is likely to hurt Cisco as it holds a dominant position in that market.
(You can read the full research report on Cisco here >>>).
Southern Company's shares have outperformed the Zacks Electric Power industry over the past six months, gaining +8.2% vs +6.8%. The Zacks analyst thinks Southern Company is one of the largest and best-managed electric utility holding companies in the United States, dominating the power business across the southeastern region.
With good rate base growth and constructive regulation, it is expected to generate steady earnings and dividend growth in the coming years through long-term power contracts. Additionally, SO's $12 billion AGL Resources buy has significantly increased its customer base and diversified offerings. However, continued timing and cost overrun issues over two large construction projects – Vogtle and Kemper – are major overhangs.
While the $25 billion Vogtle nuclear plant has gone well over budget and is years behind schedule, Southern's Kemper project suffered yet another setback with the suspension of all coal gasification operations amid additional cost burden. Hence, Southern Company warrants a cautious stance from the investors.
(You can read the full research report on Southern Company here >>>).
Other noteworthy reports we are featuring today include Exelon (EXC - Free Report) , SunTrust Banks (STI - Free Report) and AmerisourceBergen .
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6% and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>
Mark Vickery
Senior Editor
Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>